Roth Capital Reiterates Buy Rating On LeMaitre Vascular Following Recent Financing
In a research note issued this morning, Roth Capital analyst Chris Lewis reiterated coverage with a “Buy” rating on LeMaitre Vascular, Inc. (LMAT), and a price target of $10.00 a share.
“We are positive on the financing as we believe it leaves LMAT better positioned to execute on its strategic plan, including potentially larger M&A opportunities. We also expect the deal to provide some welcomed liquidity in the name”, Lewis wrote.
According to TipRanks, which measures analysts and bloggers success rate based on how their calls perform, analyst Chris Lewis, who covers LMAT, currently has a one-year average return of -2.7% and a 33% success rate, and ranked #2563 out of 3103 analysts.